SynergyFinder™ helps to ensure that new therapies are combined in the best way possible. Many cancer therapies are applied as combination therapies. To identify the right combination of your lead compound with standards of care or new drugs, NTRC has developed SynergyFinder™.
Screening 600 to 1000 combinations within a short turnaround time: your drug candidate is tested against the full library of 160 therapeutics in selected cancer cell lines within 12 weeks. If you prefer a smaller subset, we have an exemplar library of 42 therapeutics for the mechanisms that are covered in the full library. The exemplars represent the well-known and newly investigated anti cancer drugs classes. Of course, the choice of combinatorial therapeutics and cell lines is up to you.
You may prefer to test a selection of standards of care or experimental therapeutics to combine with your drug candidate. We can assist in selecting mixtures on the basis of biomarkers and targeting, as described by Uitdehaag et al. (2015) – the choice is yours. We are happy to provide cost-free consultation if desired.
The curve shift analysis determines synergy as a decrease in dose to achieve the same effect (Dose-based). The Bliss approach bases synergy on an increase in the maximum effect (Effect-based). The two methods have been merged into one approach, so that a comprehensive view on synergistic effects is generated. An advantage of the approach is that data interpretation is based on full dose response curves of the single agents and the mixtures. This approach takes the sigmoidal nature of the curves into account, covering exponential effects that may be overlooked in a dose-matrix approach.